-Omics Overdrive

Over the past five years, Global Genomics Group LLC (G3) has been steadily amassing and analyzing pan-omics data from 7,500 individuals for the identification and validation of biomarkers and therapeutic targets. Now, the company has validated its system in coronary artery disease, signed up Sanofi as its first pharma partner, and is on the hunt for more.

Read the full article here: http://www.gnshealthcare.com/wp-content/uploads/2016/02/021116IN_Tools_OmicsOverdrive.pdf

Global Genomics Group (G3) and GNS Healthcare Report Preliminary Results of Largest-Ever Study Linking Biomarkers with Coronary Artery Disease